Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 132-138

  Phernambucq, E C J ^a   Spoelstra, F O B ^a   Verbakel, W F A R ^a   Postmus, P E ^a   Melissant, C F ^b   Maassen van den Brink, K I ^c   Frings, V ^a   van de Ven, P M ^a   Smit, E F ^a   Senan, S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Infection and Immunology   (Netherlands)

^c Waterland Hospital   (Netherlands)

Author keywords

Charlson comorbidity index; Concurrent chemoradiotherapy; Patient selection; Stage III NSCLC; Toxicity

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE; PREDNISOLONE;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTERY THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ESOPHAGITIS; ESOPHAGOBRONCHIAL FISTULA; ESOPHAGUS STENOSIS; FEMALE; HUMAN; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION PNEUMONIA; THROMBOCYTOPENIA;

EID: 78650373191     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq316     Document Type: Article

References (27)

1. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
2. Vokes EE, Herndon JE II, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-1704.
3. van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99: 442-450.
4. Belderbos J, Uitterhoeve L, van Zandwijk N et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007; 43: 114-121.
5. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
6. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-5760.
7. Auperin A, Le Pechoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
8. Rowell NP, O'rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; 4: CD002140.
9. De Ruysscher D, Botterweck A, Dirx M et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009; 20: 98-102.
10. Simon GR. Treatment of older patients with non-small-cell lung cancer: walking the therapeutic tightrope. J Clin Oncol 2010; 28: 523-526.
11. Senan S, De Ruysscher D, Giraud P et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004; 71: 139-146.
12. Haasbeek CJ, Slotman BJ, Senan S. Radiotherapy for lung cancer: clinical impact of recent technical advances. Lung Cancer 2009; 64: 1-8.
13. Spoelstra FO, van Sornsen de Koste JR, Cuijpers JP et al. Analysis of reproducibility of respiration-triggered gated radiotherapy for lung tumors. Radiother Oncol 2008; 87: 59-64.
14. Landelijke Werkgroep Longtumoren. Niet-kleincellig longcarcinoom, landelijke richtlijn. VIKC 2004. URL: http://www.cbo.nl/Downloads/318/lonc-rl-2004.pdf (2 March 2010, date last accessed).
15. Senan S, Lagerwaard FJ. The role of radiotherapy in non-small-cell lung cancer. Ann Oncol 2005; 16 (Suppl 2): ii223-ii228.
16. Phernambucq EC, Spoelstra FO, Paul MA et al. Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. Eur J Cardiothorac Surg 2009; 36: 1052-1057.
17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
18. Hasenbalg F, Neuenschwander H, Mini R, Born EJ. Collapsed cone convolution and analytical anisotropic algorithm dose calculations compared to VMC++ Monte Carlo simulations in clinical cases. Phys Med Biol 2007; 52: 3679-3691.
19. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 243S-265S.
20. Fournel P, Robinet G, Thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-5917.
21. Barriger RB, Aseneau JC, Yu M et al. Rates and risk of pneumonitis in non-small cell lung carcinoma (NSCLC) patients (pts) treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2008; 72: S117-S118 (Abstr 1011).
22. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-2456.
23. van Baardwijk A, Bosmans G, Boersma L et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 2008; 71: 1394-1401.
24. van Baardwijk A, Wanders S, Boersma L et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010; 28: 1380-1386.
25. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-530.
26. Silvestri GA, Gould MK, Margolis ML et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132: 178S-201S.
27. Liao ZX, Komaki RR, Thames HD Jr et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010; 76: 775-781.